logo-loader
viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals CEO shows faith in company with $49,000 on-market purchase

To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June.

1562047717_shutterstock_727517851.jpg
Paradigm Biopharmaceuticals is focused on developing injectable pentosan polysulphate sodium (iPPS)

Paradigm Biopharmaceuticals Ltd (ASX:PAR) chief executive officer Paul Rennie has demonstrated his faith in the company with an on-market purchase of shares valued at $49,000.

Rennie purchased 35,000 shares on June 28 and now holds almost 23.415 million.

The company's securities have increased more than 2% to an intra-day high of $1.40.

READ: Paradigm Biopharmaceuticals fully funded as it advances iPPS development

Paradigm is fully funded with $78 million as it progresses development and potential commercialisation of injectable PPS (iPPS) for three indications – Osteoarthritis (OA), Mucopolysaccharidosis (MPS) and Ross River virus (RRV).

The company is now on track to file pre-investigational New Drug (IND) meeting packages for IND applications with US FDA in leading indications of OA and the Orphan indication for MPS.

Pending successful phase 3 trials, both OA and MPS have the potential to be significant commercial opportunities for Paradigm.

READ: Paradigm Biopharmaceuticals receives positive results for Ross River clinical trial

Early last month the company met its primary endpoint of safety in its pilot phase IIa clinical trial for chronic RRV induced arthralgia.

Around 18 patients were dosed, 11 with injectable pentosan polysulphate sodium (iPPS) and seven with placebos.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.8 AUD

ASX:PAR
Market: ASX
Market Cap: $540.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read